567616

Sodium 4-Phenylbutyrate

A novel anti-neoplastic agent and transcriptional regulator.

• Synonim(y): SPB, PBNa, 4PBA, 4-fenylomaślan, Na, BCKD Kinase Inhibitor I, Branched-Chain α-Ketoacid Dehydrogenase Kinase Inhibitor I, BDK Inhibitor I
• Wzór empiryczny (zapis Hilla): C₁₀H₁₁NaO₂
• Numer CAS: 1716-12-7
• Masa cząsteczkowa: 186.18
• Numer MDL: MFCD00800247
• Kod UNSPSC: 41116107
• NACRES: NA.77

Właściwości

• Poziom jakości: 100
• Próba: ≥98% (HPLC)
• Formularz: solid
• producent / nazwa handlowa: Calbiochem^®
• warunki przechowywania: OK to freeze; desiccated (hygroscopic)
• kolor: white to slightly yellow
• rozpuszczalność: water: 10 mg/mL
• Warunki transportu: ambient
• temp. przechowywania: −20°C
• ciąg SMILES: [Na+].[O-]C(=O)CCCc1ccccc1
• InChI: 1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
• Klucz InChI: VPZRWNZGLKXFOE-UHFFFAOYSA-M

Opis

Opis ogólny

A novel anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Increases fetal hemoglobin production in vitro and in vivo.

An antineoplastic agent that demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. Acts as an inducer of tumor cytostasis and differentiation as well as of peroxisomal proliferation. A more effective inhibitor of histone deacetylase and inducer of histone acetylation than its structural analogs including 2- and 3-phenylbutyrate. Acts as a transcriptional regulator and improve the targeting of δF508-CFTR (cystic fibrosis transmembrane regulator) for ubiquitination and degradation by reducing the expression of HSC70 in epithelial cells. Also, reported to increase fetal hemoglobin production in vitro and in vivo.

Działania biochem./fizjol.

Cell permeable: no

Primary Target
Anti-neoplastic agent

Product does not compete with ATP.

Reversible: no

Ostrzeżenie

Toxicity: Standard Handling (A)

Rekonstytucja

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Inne uwagi

Tso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA110, 9728.
Ozcan, U., et al. 2006. Science313, 1137.
Carducci, M.A., et al. 2001. Clin. Cancer Res.7, 3047.
Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol.278, C259.
Lea, M.A., et al. 1999. Anticancer Res.19, 1971.
Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
Collins, A.F., et al. 1995. Blood 85, 43.
Lea, M.A., et al. 1995. Anticancer Res.15, 879.
Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.

Informacje prawne

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable